Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma ...Middle East

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma )

Also on site :

• IDLES’ Joe Talbot Dedicates Primavera Sound Set to Palestine & Leads Crowd in ‘Viva Palestina’ Chant
• Yolanda Hadid ends engagement to boyfriend Joseph Jingoli after 7 years together: report
• Harrison Ford Has 2-Word Response to Seeing Jason Segel Naked